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Purpose: To evaluate efficacy and toxicity after salvage brachytherapy (BT) in prostate local recurrence after
radiation therapy.
Methods and materials: Between 1993 and 2007, we retrospectively analyzed 56 consecutively patients (pts)
undergoing salvage brachytherapy. After local biopsy-proven recurrence, pts received 145 Gy LDR-BT (37 pts, 66%)
or HDR-BT (19 pts, 34%) in different dose levels according to biological equivalent doses (BED2 Gy). By the time
of salvage BT, only 15 pts (27%) received ADT. Univariate and multivariate analyses were performed to identify
predictors of biochemical control and toxicities. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicities
were graded using Common Terminology Criteria for Adverse Events (CTCv3.0).
Results: Median follow-up after salvage BT was 48 months. The 5-year FFbF was 77%. HDR and LDR late grade 3 GU
toxicities were observed in 21% and 24%. Late grade 3 GI toxicities were observed in 2% (HDR) and 2.7% (LDR). On
univariate analysis, pre-salvage prostate-specific antigen (PSA) > 10 ng/ml (p = 0.004), interval to relapse after initial
treatment < 24 months (p = 0.004) and salvage HDR-BT doses BED2 Gy level < 227 Gy (p = 0.012) were significant in
predicting biochemical failure. On Cox multivariate analysis, pre-salvage PSA, and time to relapse were significant in
predicting biochemical failure.
HDR-BT BED2 Gy (α/β 1.5 Gy) levels ≥ 227 (p = 0.013), and ADT (p = 0.049) were significant in predicting grade ≥ 2
urinary toxicity.
Conclusions: Prostate BT is an effective salvage modality in some selected prostate local recurrence patients after
radiation therapy. Even, we provide some potential predictors of biochemical control and toxicity for prostate
salvage BT, further investigation is recommended.
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Androgen deprivation therapyIntroduction
Patients with intermediate or high risk localized prostate
cancer treated with standard dose radiation therapy with
or without ADT have a 10 year-rate of biochemical fail-
ure (BF) that ranges from 30% to 70%. Some of these
patients will die of prostate cancer [1].* Correspondence: ivanhenriquezlopez@me.com
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article, unless otherwise stated.Surgery, cryotherapy and brachytherapy are among the
most frequently used local salvage treatment options
with different degrees of success [2-11]. At the present
time, there is no consensus about what the optimal salvage
treatment should be in patients who are presumed to have
exclusive local recurrence after radiation therapy.
BT as a salvage treatment modality seems to have a
potential benefit in patients with local relapse after
radiotherapy in other solid tumors [12].
The role of ADT in combination with salvage BT in
prostate local recurrence is uncertain because the differenttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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patient sample [5,6,8-11,13].
Herein, we present the outcome and toxicity in a co-
hort of patients with locally recurrent prostate cancer
treated with salvage BT. Potential predictors of bio-
chemical failure and toxicity after salvage BT were also
identified.
Materials and methods
From January 1993 to July 2007, 56 consecutively pa-
tients with biochemical failure by ASTRO or Phoenix
definitions [14,15], and local biopsy-proven recurrence
after radiation therapy were included in this pooled-
analysis study. Eligibility criteria included a negative
evaluation of systemic disease, a good urinary and bowel
function and a life expectancy more than 5 years.
All information from these patients was collected via
retrospective chart review. The prostate biopsy specimen
was review by a pathologist of each institution who was
familiar with radiation effects on the prostate to avoid
false-positive results.
Forty-six patients (82%) were primarily treated with
(EBRT) to a median dose of 72 Gy (range, 64 Gy –
78 Gy) and 10 patients (18%) were initially treated with
LDR-BT. LDR-patients had received pre-planned D100
doses of at least 145 Gy. There was insufficient informa-
tion of the postimplant D90 values.
Other salvage options such as cryotherapy or radical
prostatectomy were discussed as well but were refused
by the patients. Written informed consent was obtained
from the patients for participation in this retrospective
review, which was approved by the Institutional Review
Boards of the participating institutions.
Salvage treatment
Patients were excluded for salvage brachytherapy if they did
not meet all of the following criteria: Qmax > 15 ml/seg,
and a prostate volume < 50 cm3.
A total of 19 (34%) patients were treated with salvage 192Ir
HDR-BTand 37 (66%) patients with salvage 125I LDR-BT.
The technique for both permanent and temporal
implant followed the local treatment policy of each
centre. The characteristics of the patients are shown in
Table 1.
The total dose to be administered with salvage brachy-
therapy, either 125I LDR-BT or 192Ir HDR-BT is yet to be
determined. We use the linear quadratic formulation for
dose equivalence. Assuming that the α/β ratio for pros-
tate is about 1.5 Gy [16], the rationale of this study was
to use an HDR-BT regimen that provided a BED2 of at
least 50 Gy EQD2 [17]. Table 2 shows the different HDR
dose levels with the corresponding BEDs values using a
α/β ratio of 1.5 and 3.0. Patients salvaged with LDR-BT
were treated with the same dose recommended by theguidelines for primary tumor in the same setting than
other authors have reported.
Although there is no specific guideline for reirradia-
tion volumes, we followed the GEC-ESTRO recommen-
dations for volume definition and dose prescription [18].
The CTV for HDR-BT included the prostate and sem-
inal vesicles (if appropriate). The CTV for LDR-BT was
the prostate only. The following parameters were recom-
mended for all investigators: V100 ≥ 95% of the CTV;
D90 > 100% of the prescribed dose. Post-implantation
CT dosimetry were recommended to be performed 4 to
6 weeks after BT for those patients treated with LDR-BT
according to the recommendations of the AAPM [19].
The mean prescription dose for salvage 125I LDR-BT was
145 Gy (range, 120 – 160 Gy). The mean prescription dose
for 192Ir HDR-BT was 50.5 Gy (range, 17 – 39 Gy),
with a mean dose per fraction of 6.2 Gy (median, 5.25 Gy
per fraction) in 1–3 implants (range, 1–4 fractions). The
mean number of plastic tubes used per implant was 13
(range, 9 – 18).
Androgen deprivation therapy
At the time of recurrence, neoadjuvant and adjuvant
ADT was used in 15 patients (HDR-BT 9 pts; LDR-BT
6 pts) during 3 and 36 months. Only three patients re-
ceived 36 months hormonal therapy. The follow-up of
these three patients from the end of hormonal treatment
was 24, 25 and 36 months, respectively.
Statistical analysis
Cancer control outcomes were calculated using the actu-
arial method of Kaplan and Meier [20]. BF was defined
following the ASTRO or the Phoenix definition [14,15].
Outcomes measured include FFbF and disease-free sur-
vival (DFS). DFS was measured from the date of BT sal-
vage until the occurrence of one of the following events,
whichever occurred first: BF, local or distant disease,
start of any treatment for prostate cancer or any cause
of death. Other outcomes evaluated included DMFS,
CSS and OS.
Univariate and multivariate analysis
For this cohort of patients, univariate and multivariate
were performed to identify potential predictors of bio-
chemical control, survival and toxicity following salvage
BT. The association of the different variables analyzed
with BF and toxicity (initial age, tumor, PSA, and Gleason
score, D’Amico risk group at initial treatment [21], initial
EBRT dose, nadir PSA post-initial treatment, time to nadir
PSA post-initial treatment, interval to relapse after initial
treatment, ADT and PSA at salvage, salvage BT dose, and
post-salvage PSA nadir) was evaluated with the Chi-square
test and their association with outcome measures was de-
termined with the log-rank test and the Cox regression
Table 1 Initial and salvage patient characteristics
Characteristics At initial
presentation
At salvage
Age (years) Mean 60 Mean 65
Range 50 - 77 Range 60 - 80
KPS Mean 80 Mean 80
Range 70 - 90 Range 70 - 90
PSA ng/ml Mean 17.3 Mean 5
Median 10.7 Median 3.7
Range 4 - 121 Range 1.1 - 30
PSA ng/ml Patients (%) Patients (%)
< 10 ng/ml 26 (46%) 51 (91%)
10-20 ng/ml 18 (32%) 4 (7%)
> 20 ng/ml 12 (22%) 1 (2%)
Gleason score Patients (%) Patients (%)
≤ 3 + 3 37 (66%) 9 (16%)
3 + 4/4 + 3 16 (29%) 14 (25%)
≥ 4 + 4 3 (5%) 8 (14%)
Unavailable 25 (45%)
T stage Patients (%) Patients (%)
T1c 23 (41%)
T2 26 (46%)
T3 7 (13%)
Unknown
Recurrent 56 (100%)
D’Amico risk group Patients (%) Patients (%)
Low 24 (43%)
Intermediate 16 (28.5%)
High 16 (28.5%)
Unknown
Radiation treatment Patients (%) Patients (%)
EBRT 46 (82.%)
< 72 Gy 24 (43%)
> 72 Gy 22 (39%)
LDR-BQT 10 (18%) 37 (66%)
HDR-BQT 19 (34%)
Time to biochemical relapse Patients Patients
(ASTRO/Phoenix definition) ASTRO PHOENIX
< 24 months 6 (11%) 4 (7%)
> 24 months 50 (89%) 52 (93%)
Androgen deprivation
therapy
Patients (%) Patients (%)
Yes 26 (46%) 15 (27%)
No 30 (54%) 41 (73%)
Table 1 Initial and salvage patient characteristics
(Continued)
Time to nadir post-RT/BQT
≤ 6 months 15 (26.8%)
6 – 12 months 7 (12.5%)
> 12 months 34 (60.7%)
Nadir PSA post-radiation Mean 0.6 ng/ml Mean 0,5 ng/ml
Median 0.5 ng/ml Median 0.16 ng/ml
Range 0.001 –
3 ng/ml
Range 0.001 –
2.9 ng/ml
LDR-BQT = low dose rate brachytherapy; HDR-BQT = high dose
rate brachytherapy.
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ered statistically significant.
Follow-up
Patients were followed-up by the Radiation Oncology
staff of the participating Institutions every 6 months, for
the first 4 years, and on a yearly basis thereafter. Toxic-
ities were recorded and graded using CTCv3.0 [22].
Results
Outcomes
With a median follow-up of 48 months (range, 25 –
109), the 5-year actuarial FFbF was 77% (Figure 1). The
5-year OS rate was 70%.
Insufficient data were available to assess the IPSS be-
fore and after treatment.
On univariate analysis, the factors associated with bio-
chemical failure were psa at salvage > 10 ng/ml (p = 0.004,
OR 16.4, 95% CI 1.82-147.7), interval to relapse after initial
treatment < 24 months (p = 0.004, OR 16.4, 95% CI 1.82-Table 2 Characteristics of salvage BT-HDR dose levels and
total BED
HDR-BT
doses
BED
(α/β = 1.5)
BED
(α/β = 3)
Total BED2 Gy
α/β = 1.5 Gy 3 Gy
8.5 Gy × 2 125 65 52 39
6 Gy × 4 132 72 55 43
9 Gy × 2 140 72 59 43
9.5 Gy × 2 154 79 65 48
6 Gy × 5 165 90 69 54
8.5 Gy × 4 227 130 95 78
9 Gy × 4 279 144 116 86
10.5 Gy × 3 280 140 117 84
9.5 Gy × 4 308 158 119 95
13 Gy × 3 419 208 240 206
HDR-BT = high dose rate brachytherapy; BED = biological equivalent doses;
α/β = alfa/beta; BED2 Gy = biological equivalent doses at 2 Gy per fraction.
Figure 1 Kaplan-Meier freedom from biochemical failure post-salvage brachytherapy with 5-year estimates.
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(p = 0.012, OR 18, 95% CI 1.75-184.8). Nadir PSA > 1 ng/ml
at relapse was of borderline significance in predicting
BF (p = 0.087, OR 4.35; 95% CI, 0.73-25.6).
On Cox multivariate analysis, PSA at relapse > 10 ng/ml
(p = 0.043, OR 0.181, 95% CI 0.03-0.84), and time to
relapse < 24 months (p = 0.031, OR 0.160, 95% CI 0.057-
0.571) was strongly associated with biochemical failure.
The factors significantly associated with Grade ≥ 2 urin-
ary toxicity were androgen deprivation therapy at relapse,
and HDR-BT at salvage (BED2 Gy level ≥ 227) (Table 3). No
factor predictive of rectal toxicity was found.
At the time of this analysis, only one patient had died
of prostate cancer at 25 months from salvage BT.
Toxicity
HDR-BT urinary toxicity
Three out of the 19 patients did not develop any urinary
toxicity. Four patients (21%) had Grade 3 toxicity requiring
medical support or intervention for symptom reliefTable 3 Multivariate analysis of factors that may
influence Grade ≥ 2 urinary toxicity
Factor OR (95% CI) p value
ADT at relapse (yes vs. not) 0.494 (0.245-0.997) 0.049
HDR-BT at salvage 0.459 (0.242-0.870) 0.017
BED2 Gy level≥ 227 vs
BED2 Gy level < 227
ADT = androgen deprivation therapy; OR = odd ratio; HDR-BT = high dose rate
brachytherapy; BED2 Gy = biological equivalent doses.(urethral stricture that interfered in daily activities requiring
periodical dilations n = 4). There were no cases of Grade 4
or greater urinary toxicity.
LDR-BT urinary toxicity
Eight out of 37 patients did not develop any urinary tox-
icity. Nine patients (24%) had Grade 3 toxicity (bladder
sphincter spasms requiring narcotics, n = 3; obstructive
uropathy requiring TURP after 36 months from salvage
therapy, n = 5). There were no cases of Grade 4 or greater
urinary toxicity.
HDR-BT rectal toxicity
Thirteen of 19 patients did not develop rectal toxicity.
One patient (2%) developed a Grade 3 rectal event con-
sisting of persistent rectal bleeding requiring argon laser
therapy with complete resolution.
LDR-BT rectal toxicity
Nineteen out of 37 patients did not develop any rectal
toxicity. One patient (2.7%) had Grade 4 rectal toxicity
that consisted of a prostatorectal fistula. This patient re-
quired colostomy 24 months after salvage therapy. There
were no cases of Grade 3 or 5 rectal toxicities.
The information available to assess the rates of erectile
dysfunction after salvage BT was not complete enough
to report on this item.
Discussion
The present study represents, to the best of our know-
ledge, the largest series of salvage BT ever published.
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with a corresponding 5-year OS and a CSS rate of 70%
and 97%, respectively. These results are comparable with
other prior reports on salvage BT (5,6,8-11).
The evidence published at literature of salvage BT
varies according to patient and disease-related char-
acteristics and suggests a wide range of outcomes
and toxicities. For properly selected patients with local
failure after definitive RT, salvage BT can provide long-
term disease control comparable with other salvage
modalities.
Even the mid-term follow-up of this study is lim-
ited, our study of salvage BT found a high 5-year bio-
chemical control rate and it provides durable disease
control in a substantial percentage of patients after local
recurrence of prostate cancer despite previous definitive
RT.
Biochemical failure after primary radiation in localized
prostate cancer occurs after 60 months, and therefore a
longer follow-up is desirable to analyze how the impact
of treatment should be. However, in a salvage treatment
(surgery, cryotherapy, brachytherapy), the oncology situ-
ation is different probably because of tumor cell becomes
more resistant to salvage treatment and therefore many of
BF is expected to be in the first 5-year after treatment.
This situation is frequently to be observed in other solid
tumors.
Chen [9], in a salvage HDR-BT study of 52 patients
had a BF of 49% at 5-year. Most of these failures occur
before 48 months after treatment. A study with 37 pa-
tients from Mount Sinai Medical Center [11] examined
the role of salvage LDRB for local failure after prostate
radiation therapy. The 5-year BF reported was 35.5%.
Only a 11% more of BF was observed at 10-year.
In addition, the mean of follow-up of most relevant
salvage brachytherapy series published from 1999 is
52 months (30 – 86 months). The majority of BF of the
series are reported at 5-year [3,4,6,8,9], except one author
[11], at 10-year (Table 4).
Our-study revealed that 23% of BF occur in the first
5-year, and hormonal treatment at relapse did not have any
influence on BF (p = 0.126, OR 0.298, 95CI 0.063 – 1.4).
At this moment, if there is a suspicious of failure by a
rising of PSA after radiation therapy, physical exam with
rectal examination, magnetic resonance imaging, bone
CT-scan and biopsy-proven histology are strongly recom-
mended before a patient could be offered a salvage treat-
ment. Even, there is an estimation of 70% of relapse are
localized at prostate, these biological, clinical and radio-
logical methods are insufficient to demonstrate whether
the relapse is local or not. However, in the last years, some
prognostic factors have been identified at diagnosis, at ini-
tial treatment and at relapse which are associated with
lower rates of PSA recurrence by 5 years after any of thesalvage local therapies [1]. These factors should be taken
into account because they may help to identify the best
candidate to offer salvage brachytherapy, as it is suggest by
other authors [1].
The consensus of ASTRO (1997) and Phoenix (2005)
clearly defined PSA failure after radiation therapy [14,15].
Actually, it is not possible to make definitive statements of
PSA failure after salvage brachytherapy because of wide
variety of PSA definition reported at literature [3-11]. In
our study, the Phoenix criteria were used for relapse after
salvage brachytherapy as it was considered by some recent
publications [7,9-11].
A number of predictive factors have been related with
the risk of subsequent failure and toxicity in patients
with local failure treated for salvage [1,9,11,23-26]. To
facilitate a better patient selection for salvage BT, our
study revealed that the disease-free interval after initial
definitive RT, the prior salvage PSA, and salvage HDR-
BT doses (BED2 Gy level ≤ 227) were each of significance
in predicting biochemical control after salvage BT. Also,
nadir PSA > 1 ng/ml after salvage BT was of borderline
significance (p = 0.087).
A larger interval of disease-free after initial definitive
radiation therapy may suggest local rather than regional/or
distant disease recurrence. Chen [9] found a borderline sig-
nificance in predicting biochemical failure in those patients
with a prolonged disease-free interval after initial definitive
radiation therapy.
Presalvage PSA is an important predictor of outcome
for salvage brachytherapy.
Burri [11] showed a trend for increased freedom from
BF in patients with low PSA at the time of salvage LDR.
In the postoperative RT literature, earlier salvage exter-
nal beam RT, results in higher progression-free survival
when the presalvage PSA is lower [24]. Similar to other
modalities, salvage RP is more effective when the pre-
operative PSA is lower [23,27].
Although elevated Gleason score [23], extended in-
terval from first recurrence to time to earlier salvage
RT [24] and percent positive cores biopsies [9,26] have
been found to be a predictor of BF and disease pro-
gression, in our salvage BT study we did not find any
correlation.
However, only a prospective randomized trial can make
definitive statements in PSA failure and prognostic factors
after salvage brachytherapy.
The occurrence of relevant treatment adverse effects
combined with otherwise good results in terms of cancer
control have led to a growing interest in evaluating the
impact of treatment on quality of life (QoL).
Surgery, radiation therapy or brachytherapy alone or
associated to hormonal treatment is an effective treat-
ment but caused urinary, bowel, or sexual dysfunction
with different frequency, duration, and severity. Radical
Table 4 Salvage brachytherapy series after local failure of radiation therapy for prostate cancer
Study, year Salvage brachytherapy doses N Pre-salvage PSA (ng/ml) Median f/u (mo) Outcome Grade 3/4 toxicity
Grado et al., 1999 [4] LDR 145 Gy 49 5.6 64 34% 5-y bDFSa 16%
56% 5-y bDFSb
Beyer et al., 1999 [3] LDR 120 Gy 125I 17 2.2 62 53% 5-y FFSRc NR
90 Gy 103P
Wong et al., 2006 [5] LDR 126 Gy 17 4.7 44 75% 4-y FfbFc 47%
Allen et al., 2007 [6] LDR 97 Gyd 12 3.8 45 63% 5-y FfbFc 0%
Chen et al., 2013 [9] HDR 36 Gy 52 9.3 59.6 51% 5-y FfbFe 2%
Nguyen et al., 2007 [7] LDR 137 Gyf 25 9.46 46 70% 4-y FfbFe 30%
Lee et al., 2008 [8] LDR 90 Gyg 21 3.8 36 38% 5-y FfbFc 0%
Aaronson et al., 2009 [10] LDR 144 Gy 24 3.4 30 89% 3-y FfbFe 4%
Burri et al., 2010 [11] LDR 135 Gy 125I 37 5.6 86 65% 5-y FFbF 11%
110 Gy 103P 54% 10-y FfbFe
Current series, 2013 HDR (BED2 Gy) 125–419 Gy 56 5 48 77% 5-y FFbF
e HDR GU/GI
G3.......21%/2%
LDR 145 Gy LDR GU/GI
G3.....24%/0%
G4.....0%/ 2.7%
LDR = low dose rate; HDR = high dose rate; bDFS = biochemical disease-free survival; FFSR = freedom from second relapse; NR = not reported; GU = genitourinary;
GI = gastrointestinal; G3 = grade 3; G4 = grade 4.
aFailure defined as two PSA rises above nadir.
bNadir psa < 0.5 ng/ml.
cFailure defined as ASTRO definition.
dMedian dose.
eFailure defined as Phoenix definition.
fMedian minimum peripheral dose.
gMinimum peripheral dose.
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dysfunction but improved preexisting urinary irritative-
obstructive symptoms. External radiotherapy and brachy-
therapy caused urinary irritative-obstructive adverse effects
and some sexual dysfunction. External radiotherapy also
caused bowel adverse effects [28,29].
Although salvage treatment (surgery, cryotherapy,
brachytherapy) is associated with reasonable cancer control
outcomes, sexual, rectal and urinary dysfunction is the
mainstay limitations for preserving quality of life (QoL).
Actually, there is not prospectively data available in QoL in
patients treated with salvage treatment. Most of data re-
ported are based on functional outcomes instead of vali-
dated QoL instruments [10,11].
In our study, there were some exclusion criteria based
on Qmax and prostate volume, and also, some technical
recommendations and a quality parameters of brachy-
therapy treatment based on GEC-ESTRO guidelines for
volume definition and dose prescription. Although these
recommendations are insufficient, they are useful to
minimize toxicity in urethra, rectal, bladder and sexual
function from brachytherapy treatment. While we were
unable to document the IPPS on follow-up, at baselinethese men had generally good urinary function before
BT. The lack of patient questionnaires make this obser-
vation circumspect.
Nowadays, there is a strong recommendation to use
QoL instruments in future trials of salvage brachytherapy.
Urinary toxicity profile is very important in patients
who undergone salvage brachytherapy.
Recently, Chen [9], reported in 52 patients with local
recurrence after radiation therapy treated with salvage
HDR-BT an acute and late grade 3 GU toxicities in only
2% and 2%, respectively. In this study, all patients re-
ceived the same salvage treatment with the same total
HDT-BT dose and fractionation. The authors did not re-
ported any Grade 4 or 5 GU toxicity. The explanation of
this low GU toxicity may be a selection of patients with
low urinary toxicity at baseline (even the authors did not
reported any based-QoL instruments such as IPSS), and
the homogeneous procedure applied in technique, dose
and fractionation with HDR-BT. In addition, the urethral-
sparing technique included [30] may help limit the rate of
urethral stricture. This is the lowest urinary toxicity pub-
lished with this technique when it is compare with other
salvage brachytherapy series [1,4,5,7,10,11,25].
Table 5 Most relevant average toxicities of different
salvage techniques
Salvage technique Incontinence Rectal
injury
Bladder neck
stricture
Fistula
Prostatectomy
[23,27]
41% 4.7% 24%
Cryotherapy
[26,31,32]
36% 17% 2.6%
Brachytherapy
[1,3-5,7-11]
6% 5.6% 17% 3.4%
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21% and 24% in patients salvaged either with HDR or
LDR, respectively. Several factors may explain this GU
toxicity, such as, different techniques of brachytherapy,
doses and fractionations. Also, we did not quantified any
qualified urinary instruments (IPSS) that helped to select
a patient with a good urinary function before salvage
BT. All these factors may contribute to have a high urin-
ary toxicity.
Even, the GU toxicity in our study are high, the ob-
served rate averaged those described in former reports
[1,4,5,7,10,11,25]. The mean average urinary toxicity
from salvage BT series are incontinence in 6% and ureth-
ral stricture in 17%, respectively. In addition, when we
compared with other salvage modalities, the urinary tox-
icity profile of our study is acceptable. For example, sal-
vage prostatectomy has an associated incontinence rate
of 45% (range:0%-80%) and salvage cryoablation can
result in incontinence rates ranging from 4.7% to 95%
(Table 5).
A better selection of presalvage BT patients with good
urinary function (IPSS < 8 or AUA < 10 scores), and the
use of an urethral-sparing technique [30] may help to
decrease urinary morbidity.
The results of the present study are far from conclu-
sive due to the wide variability of patients, treatment
characteristics regarding BT type, doses and ADT sched-
ule. The retrospective nature of the study and it’s a po-
tential for selection bias may preclude the identification
of some patient and treatment-related factors that might
influence on outcomes or toxicities.
Nonetheless, even these limitations, we still demon-
strated a consistent disease control in a majority of pa-
tients. In addition, we identified some potential predicting
factors for local control and urinary toxicity that are in line
with predictors identified for other salvage modalities.
However, we must be cautious to further investigate these
predicting factors of outcome and toxicity in prospective
trials.
Prospective multi-institutional trials (Radiation Therapy
Oncology Group 0526) and the Spanish phase II trial
(Anabraq) of salvage BT with or without ADTare currently
open to accrual to address these concerns.Conclusions
This pooled-analysis study has demonstrated that BT,
with careful selection criteria is a feasible salvage treat-
ment after EBRT failure. Even, we identified some pre-
dictors of biochemical control and urinary toxicity that
may help patient selection for prostate salvage BT, fur-
ther investigation is recommended in future trials.
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